The Society for Eczema Studies (SES) held a continuing medical education (CME) program titled 'Atopic Dermatitis Update 2026' in Varanasi, India, focusing on the latest advancements in treating atopic dermatitis (AD). This inflammatory skin disorder is a major public health concern, affecting nearly 10% of adults and up to 20% of children worldwide. In India, its prevalence varies between 0.98% and 9.2%, influenced by changing environmental factors. Experts emphasized that AD can severely impact quality of life, leading to chronic itching, sleep disturbances, and emotional distress. Dr. Sandipan Dhar, president of SES, highlighted the need for increased recognition of this condition and the importance of sharing emerging evidence among dermatologists. The CME also discussed treatment gaps despite existing therapies, including DMARDs and biologics. Newer therapies, such as JAK inhibitors like Tofacitinib and Upadacitinib, have been approved by the USFDA and may provide faster relief and improved treatment outcomes for moderate-to-severe cases.